Effectiveness of simvastatin on multiple sclerosis (MS)
Phase 2
- Conditions
- Multiple sclerosis.Multiple sclerosis
- Registration Number
- IRCT2015112925284N1
- Lead Sponsor
- Vice Chancellor for Research, Arak University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Relapsing-remitting MS patients; at least 1 relapse in the previous 12 months; more than three lesions on spinal or brain magnetic resonance imaging or both; baseline expanded disability status scale (EDSS) from 0 to 3.5; aged 18–60 years.
Exclusion criteria: clinical CIS syndrome, progressive MS, MS patients with acute clinical relapses occurring during the study, drug abuse, renal failure, pregnancy, hepatitis diseases.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Assay of cell amplification of peripheral blood luokocytes. Timepoint: 6 months after entering the intervention. Method of measurement: MTT assay.
- Secondary Outcome Measures
Name Time Method evel of cytokines. Timepoint: 6 months after entering the intervention. Method of measurement: ELISA.